Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Ascletis Pharma's operating assets for the quarter that ended in Dec. 2025 was $23.52 Mil. Ascletis Pharma's operating liabilities for the quarter that ended in Dec. 2025 was $18.05 Mil. Ascletis Pharma's Total Assets for the quarter that ended in Jun. 2025 was $278.10 Mil. Therefore, Ascletis Pharma's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.02.
Ascletis Pharma Scaled Net Operating Assets Related Terms
Ascletis Pharma Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Ascletis Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.02 mean?
Ascletis Pharma (ASCLF) has a Scaled Net Operating Assets of 0.02 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Ascletis Pharma and its competitors.
Is Ascletis Pharma's Scaled Net Operating Assets too high?
Ascletis Pharma's current Scaled Net Operating Assets is 0.02. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Scaled Net Operating Assets compare to VRTX and REGN?
Ascletis Pharma's Scaled Net Operating Assets of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Ascletis Pharma and its competitors. Ascletis Pharma's current Scaled Net Operating Assets is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Scaled Net Operating Assets is 0.02. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Scaled Net Operating Assets is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Scaled Net Operating Assets: 0.02
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
